GlassScriptPhysician profile
Roger M Kao
NPI 1982786133
$20,709.80
in general payments reported to CMS, 2019-2025
39 companies · $3,995 in 2025
The $3,995 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,665 · 2020: $2,973 · 2021: $3,115 · 2022: $2,643 · 2023: $2,513 · 2024: $2,806 · 2025: $3,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,247 · Education: $66.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,246.61 |
| Education | $66.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,218.77 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,194.28 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $2,182.88 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $1,673.23 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $1,562.80 | 2019-2025 | |
| Qol Medical, LLC | $900.90 | 2019-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $700.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $643.00 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $402.73 | 2019-2025 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $399.51 | 2020-2025 | Linzess |
| Celltrion USA INC. | $392.29 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Allergan, INC. | $380.75 | 2019-2020 | |
| Daiichi Sankyo INC. | $374.87 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $360.48 | 2019-2024 | Dificid |
| Lilly USA, LLC | $353.66 | 2023-2025 | Omvoh |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $351.20 | 2020-2023 | Aemcolo, Talicia, Movantik |
| Intercept Pharmaceuticals, INC. | $341.51 | 2019-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $244.24 | 2019-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $238.83 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $233.83 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $228.40 | 2024-2025 | Zenpep |
| Romark Laboratories, Lc | $182.44 | 2019-2020 | |
| Vivus LLC | $170.10 | 2021-2025 | Pancreaze |
| Celgene Corporation | $121.55 | 2021-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $117.70 | 2024-2025 | Iqirvo, Bylvay |
| Pfizer INC. | $109.97 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $92.75 | 2020-2023 | |
| Amgen INC. | $79.86 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $75.27 | 2022-2023 | Dupixent |
| Genzyme Corporation | $64.04 | 2021-2023 | |
| Exact Sciences Corporation | $60.79 | 2024-2025 | Cologuard Collection Kit |
| Echosens North America, INC. | $57.60 | 2024-2025 | Fibroscan, Fibroscan |
| Novo Nordisk INC | $51.49 | 2025 | Wegovy |
| Endo Pharmaceuticals INC. | $36.70 | 2019 | |
| Biocon Biologics INC | $31.34 | 2025 | Yesintek |
| Sandoz INC. | $22.91 | 2023 | Hyrimoz |
| Shire North American Group INC | $22.62 | 2019 | |
| Cook Medical LLC | $18.24 | 2021 | |
| Capsovision, INC. | $15.96 | 2025 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Kao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.